AIA, Tencent, Fosun, NWS Holdings and Tyan Home could exit the medical booking platform in an initial public offering valuing it at more than $10bn.

The Taiho Ventures, Memorial Sloan and Hartford HealthCare Endowment-backed cancer drug developer has filed to raise up to $86.3m.

Chinese Academy of Sciences and its VC subsidiary TCL Capital are in line to exit the artificial intelligence chip producer, which was valued at $2.5bn as of 2018.

Alibaba, Lenovo, Tuling Century and iFlytek are in line to exit the artificial intelligence chip producer, which was valued at $2.5bn as of 2018.

The Comcast, McKesson, Humana and Independence Health-backed digital health concierge developer has set an initial target of $100m for its proposed flotation.

Valued at $13bn in November, SoftBank-backed food delivery platform developer DoorDash has confidentially filed for an initial public offering.

University of Pennsylvania-linked Passage Bio issued 4.6 million more shares than originally planned to raise $216m, up more than 70% on its $125m original target.

Oncology therapy developer Revolution Medicines went public giving an exit to pharmaceutical company Sanofi.

The Chalmers University of Technology back pain injection spinout floated in an IPO that was oversubscribed by more than four-fold.

The sickle cell disease drug developer, which is backed by Pfizer Ventures and Lundbeckfonden Ventures, has filed for an $86.3m IPO.